A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Gemcitabine (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 12 Dec 2017 Planned End Date changed from 1 Jun 2021 to 31 May 2023.
- 12 Dec 2017 Planned primary completion date changed from 1 Jun 2021 to 31 May 2018.
- 12 Dec 2017 Status changed from recruiting to active, no longer recruiting.